At the end of the latest market close, Cardiff Oncology Inc. (CRDF) was valued at $12.18. In that particular session, Stock kicked-off at the price of $11.59 while reaching the peak value of $12.36 and lowest value recorded on the day was $11.21. The stock current value is $14.85.
Cardiff Oncology Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $14.84 on 09/29/20, with the lowest value was $0.70 for the same time period, recorded on 03/19/20.
Get Ready for my next COVID-19 stock idea. I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. Our goal for our members is to get our Alert’s first before the crowd.
Cardiff Oncology Inc. (CRDF) full year performance was 728.57%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Cardiff Oncology Inc. shares are logging 20.15% during the 52-week period from high price, and 2018.40% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.70 and $12.36.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2264395 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Cardiff Oncology Inc. (CRDF) recorded performance in the market was 882.26%, having the revenues showcasing 139.76% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 266.25M, as it employees total of 14 workers.
Specialists analysis on Cardiff Oncology Inc. (CRDF)
During the last month, 1 analysts gave the Cardiff Oncology Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 5.12, with a change in the price was noted +13.38. In a similar fashion, Cardiff Oncology Inc. posted a movement of +1,124.73% for the period of last 100 days, recording 1,526,052 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CRDF is recording 0.01 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.01.
Trends and Technical analysis: Cardiff Oncology Inc. (CRDF)
Raw Stochastic average of Cardiff Oncology Inc. in the period of last 50 days is set at 97.48%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 97.43%. In the last 20 days, the company’s Stochastic %K was 94.46% and its Stochastic %D was recorded 89.42%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 882.26%. Additionally, trading for the stock in the period of the last six months notably improved by 1082.52%, alongside a boost of 728.57% for the period of the last 12 months. The shares increased approximately by 5.00% in the 7-day charts and went down by 62.62% in the period of the last 30 days. Common stock shares were driven by 139.76% during last recorded quarter.